ARCHIVED - Canadian Adverse Reaction Newsletter, Volume 21 - Issue 1 - January 2011
Cat no H42-4/1-21-1E
Health Products and Food Branch
Marketed Health Products Directorate
Canadian Adverse Reaction Newsletter Editorial Team
In this Issue:
This quarterly publication alerts health professionals to potential signals detected through the review of case reports submitted to Health Canada. It is a useful mechanism to stimulate adverse reaction reporting as well as to disseminate information on suspected adverse reactions to health products occurring in humans before comprehensive risk-benefit evaluations and regulatory decisions are undertaken. The continuous evaluation of health product safety profiles depends on the quality of your reports.
Reporting Adverse Reactions
Canada Vigilance Program
For more information on how to report an adverse reaction, visit the Adverse Reaction and Medical Device Problem Reporting page.
Caveat: Adverse reactions (ARs) to health products are considered to be suspicions, as a definite causal association often cannot be determined. Spontaneous reports of ARs cannot be used to estimate the incidence of ARs because ARs remain underreported and patient exposure is unknown.
Clozapine and life-threatening gastrointestinal hypomotility
- Health care professionals are reminded of life-threatening gastrointestinal hypomotility suspected of being associated with the use of clozapine.
- Patients taking clozapine should be advised to notify their health care professional if constipation occurs or worsens.
- Gastrointestinal hypomotility may be aggravated by combining clozapine with other potentially constipating medications.
Clozapine is an atypical antipsychotic agent indicated in the management of treatment-resistant schizophrenia.Footnote a1 It has been marketed in Canada since 1991 under the brand name Clozaril and is now also available as generic products. Clozapine use is limited to patients who have not responded to, or are intolerant of, conventional antipsychotic medications. Constipation is a common adverse reaction (AR) to the drug. The Canadian product monograph for Clozaril indicates that constipation occurred in 14% of patients in clinical trials, and higher rates have been reported in case series.Footnote a1Footnote a2 The Canadian product monograph also lists paralytic ileus as a contraindication to clozapine use.Footnote a1 The drug has potent anticholinergic effects that have been associated with varying degrees of impairment of intestinal peristalsis, from constipation to intestinal obstruction, fecal impaction and paralytic ileus.Footnote a1 On rare occasions, these cases have been fatal.
Clozapine's anticholinergic and antiserotonergic effects may contribute to gastrointestinal hypomotility and colonic distension.Footnote a2Footnote a3Footnote a4 Intraluminal distension in turn can compromise capillary circulation and lead to colonic mucosal ischemia. In addition, severe fecal retention resulting from hypomotility may promote colonic distension, accumulation of gas and fluids, and bacterial proliferation in the affected bowel segment.Footnote a3,Footnote a4 Bacteria may then invade the underlying ischemic mucosa, resulting in necrosis and systemic sepsis.
The potential for complications and death from severe gastrointestinal hypomotility is considerable.Footnote a2,Footnote a5 For instance, the rate of death from acute colonic pseudo-obstruction (acute colonic dilatation without mechanical obstruction) is 15% in the absence of complications such as ischemia and perforation.Footnote a5 If spontaneous perforation occurs (3% -15% of cases), mortality rises to 50% or higher.Footnote a5 Late presentation and diagnosis of bowel obstruction may contribute to fatal outcomes in patients using clozapine.Footnote a2 This may be related to diminished pain sensitivity in patients with schizophrenia or to difficulty in expressing their pain.Footnote a2,Footnote a6 In addition, concomitant medications may have sedative and analgesic effects, which may mask or attenuate early symptoms and contribute to delayed diagnosis.
As of July 15, 2010, Health Canada received 704 reports of gastrointestinal ARs suspected of being associated with the use of clozapine. Of these, 28 deaths involving people with ARs related to intestinal obstruction were identified. Reports came from health care professionals and the medical literature.Footnote a4,Footnote a7 For these 28 cases, the quality of reporting varied. Many reports did not exclude other possible causes of bowel obstruction. Six cases were considered difficult to assess because the reports contained limited or conflicting clinical information. Of the remaining 22 cases, 13 involved men and 9 involved women. The median age of patients was 61 years. A prior history of constipation was noted in 6 reports. Thirteen reports involved the use of other medications with the potential to cause or aggravate constipation. Examples included other antipsychotic agents (e.g., methotrimeprazine, loxapine and olanzapine), medications used to manage drug-induced extrapyramidal symptoms (e.g., benztropine and procyclidine) and medications indicated for the treatment of urinary tract disorders (e.g., oxybutynin and tolterodine). Use of a laxative before the intestinal obstruction developed was reported in 4 cases. The total daily dose of clozapine, reported in 17 cases, varied from less than 300 mg (5 cases) to more than 600 mg (2 cases). The median daily dose in the remaining 10 cases was 550 mg. Time to onset of ARs ranged from about 2 weeks to many years. In 3 cases, death was related to aspiration pneumonia associated with ileus.
Health care professionals are reminded of the potential for life-threatening gastrointestinal hypomotility suspected of being associated with the use of clozapine. It has been recommended that patients taking clozapine should be monitored for the development of constipation and that appropriate therapy be instituted in a timely manner to prevent complications.Footnote a2 Symptoms of serious gastrointestinal complications may be nonspecific and may include abdominal pain or distension, vomiting, constipation, change in bowel habit and fever.Footnote a2 Whenever possible, concomitant use of other medications with the potential to cause or aggravate constipation, particularly those with anticholinergic properties, should be avoided.Footnote a2,Footnote a7
Erin Smith, MD, Danielle Brûlé-Brown, MD, Health Canada
Recent Canadian cases are selected based on their seriousness, frequency of occurrence or the fact that the reactions are unexpected. Case presentations are considered suspicions and are presented to stimulate reporting of similar suspected adverse reactions.
Bio-Alcamid soft-tissue endoprosthesis: suspected association with late infection
Bio-Alcamid is a colourless, gelatinous injectable filler consisting of 4% synthetic amide-imide alkyl-type polymer and 96% nonpyrogenic water.Footnote 1 In Canada, this product is regulated as a medical device and is indicated for the treatment of facial lipoatrophy resulting from the use of antiretroviral medications. When injected subcutaneously, Bio-Alcamid can restore lost volume in facial areas that have been depleted, typically in the regions of the temples and cheeks.Footnote 1 Its use may help restore natural facial structure and contours.
In April 2009, Health Canada received a report of a patient with massive left-sided facial swelling. A buccal space infection was diagnosed. The infection was suspected of being associated with Bio-Alcamid material that had been implanted in 2006. The affected area was incised and drained; the implanted material had become infected and was removed. Similar late complications, including reports of infection and migration occurring one year or more after Bio-Alcamid injection, have been described in the literature.Footnote 2,Footnote 3,Footnote 4 Cases of late infection associated with Bio-Alcamid have been described involving patients with and without a recent history of possible triggering events such as local trauma or medical and dental interventions.Footnote 2,Footnote 3 The medical literature also suggests that the resultant abscesses may be challenging to treat and may recur or persist after medical or surgical intervention.Footnote 3,Footnote 4
Health Canada encourages the reporting of adverse incidents suspected of being associated with Bio-Alcamid to the Health Products and Food Branch Inspectorate through the toll-free hotline (1-800-267-9675).
Natural health product identification in adverse reaction reports
Health product identifiers: more than just a name!
It is important to include as many health product identifiers as possible in the adverse reaction reporting form.
- Exact product brand name (including modifying prefix or suffix)
- Natural Product Number (NPN), Exemption Number (EN) or Homeopathic Medicine Number (DIN-HM)
- List of ingredients (or a copy or picture of the label or container) and their amount per serving
- Lot number
- Expiration date
- Company name
- Where the product was purchased (e.g., Internet, pharmacy, ethnic store)
Under the Natural Health Products Regulations, which came into effect on Jan. 1, 2004, natural health products (NHPs) are defined as vitamins and minerals, herbal remedies, homeopathic medicines, traditional medicines such as traditional Chinese medicines, probiotics, and other products such as amino acids and essential fatty acids. Thousands of NHPs are available directly to Canadian consumers off store shelves (e.g., at supermarkets, health food stores, pharmacies and ethnic stores) or through other means (e.g., the Internet and personal importation). To properly evaluate safety issues associated with NHPs, Health Canada needs your help in providing quality reports of adverse reactions (ARs).
According to international guidelines, the minimum data elements needed for an AR report are patient information, description of the reaction, information about the suspected health product and the reporter's contact information.Footnote c1 However, more comprehensive information, such as details about the suspected NHP(s) or concomitant health product(s) (see examples of health product identifiers in the box above), is needed to ensure the quality and usefulness of the report. For instance, provision of the NHP's ingredient list allows for identification of an ingredient known for its association with an AR, or its potential for interaction, or for overdose if several products with the same ingredient are used concomitantly. The lot number and company name allow for more efficient regulatory actions when cases of adulteration or contamination are suspected.
Several factors may confound the identity of an NHP in reports of ARs submitted to Health Canada, which may limit the ability to assess the data. These factors include:
- Existence of products with the same or similar brand names, such as line-extension products, that contain different active ingredients.
- Identification in the AR report of a health product by a common name without further information such as dosage preparation, other medicinal ingredients or plant species.
- Presence of multiple products with different brand names under a single Natural Product Number (NPN) or Exemption Number (EN).
- Reformulation of NHPs over time (e.g., change of medicinal ingredients or their quantity, and change of dosage form) but retention of the same brand name.
- Possibility of confusion with unauthorized NHPs, which have not been evaluated by Health Canada for quality, safety and efficacy, and which may be adulterated or counterfeit.
Health professionals are encouraged to ask patients about any NHPs they are taking, to document relevant product information and to report to Health Canada's Canada Vigilance Program any ARs suspected of being associated with their use.
Karen Kouassi, MSc, Health Canada
Quarterly Summary of health professional and consumer advisories
|Nov 12||Breastlight||Recall of unathorized breast cancer screening device|
|Nov 4||Medical device clocks||Reminder to switch to Standard Time|
|Nov 4||Unauthorized products||Removal of unauthorized health products in Vancouver Island stores|
|Nov 3||Prescription drugs online||Warning about buying prescription drugs online|
|Oct 27 & Nov 2||Invirase||Updated prescribing information|
|Oct 26 & 29||Emo-Cort (hydrocortisone) 2.5% Lotion||Recall of Lot 5R6|
|Oct 28||GlucaGen Hypokit||Recall|
|Oct 27||Hyland's Teething Tablets||Recall|
|Oct 14 & 19||Innohep||Updated safety information on use in elderly patients with renal impairment|
|Oct 14||Bisphosphonate drugs||Possible risk of rare but serious thigh bone fractures|
|Oct 12 & 14||Aclasta||Association with renal dysfunction|
|Oct 8, 13 & 14||Sibutramine drugs||Voluntary withdrawal from the Canadian market|
|Oct 5||Calcium supplements||Ongoing review|
|Oct 4 & 5||Pegetron||Important information regarding quality, safety and supply|
|Oct 4||Level 1 Normothermic IV Fluid Administration Sets||Recall concerning a heat exchanger assembly manufacturing issue|
|Sep 20||Foreign products||Alerts: Golden aryuru, Baisheng wei ge, Zhonghua niubian, Ten ka dai 1 bou, Kuai gan bei zeng chao yue zi wo (Happy felling doubly increase [sic]), Ling tou lang, SkyFruit, Chu bi ho ken, Jinbolang, Suika Koso, Lov, I ka ou (2009 nen sin hoso) and/or I ka ou (saisinsui shutsu hoso); Vialipro; Joyful Slim Herb Supplement|
|Sep 15||"Arth-Forth"||Unauthorized herbal product may pose serious health risks|
|Sep 13 & 16||Actemra||Risk of fatal anaphylaxis|
|Sep 13||"E.O.D. Erection on Demand"||Unauthorized health product may pose serious health risks|
|Sep 7||Alaris PC unit||Total bolus display error|
|Sep 4||Excelsior Disposable Syringe||Recall|
|Aug 31||Human papillomavirus (HPV)||It's Your Health update|
|Aug 26||Topical hemostatic agents||Delivery using spray devices - association with air/gas embolism|
|Aug 25||Droperidol Injection USP||Association with severe arrhythmia|
|Aug 25||GlucaGen Hypokit||Recall|
|Aug 23||Stander (Tilt Standing Frame)||Addition to safety warning label|
|Aug 19 & 23||Avastin||Association with allergic reactions|
|Aug 9||Gemstar Pump Sets||Recall|
To receive the Newsletter and health product advisories free by e-mail, subscribe to MedEffect e-Notice.
Canadian Adverse Reaction Newsletter
Marketed Health Products Directorate
Address Locator 0701D
Ottawa ON K1A 0K9
Ann Sztuke-Fournier, BPharm (Editor-in-Chief)
Jared Cousins, BSP
Mary Joy, RPh, BScPhm
Hoa Ly, BSc
Patricia Carruthers-Czyzewski, BScPhm, MSc
Gilbert Roy, BPharm
Christianne Scott, BPharm, MBA
We thank the following members of the Expert Advisory Committee on the Vigilance of Health Products for their review of material for this issue: Colleen J. Metge, BSc(Pharm), PhD; Dugald Seely, ND, MSc; and Sylvia Hyland, RPh, BScPhm, MHSc.
Your comments are important to us. Let us know what you think.
Canadian Adverse Reaction Newsletter (CARN) Editorial Team
Reporting Adverse Reactions
Canada Vigilance Program
© 2011 Her Majesty the Queen in Right of Canada. This publication may be reproduced without permission provided the source is fully acknowledged. The use of this publication for advertising purposes is prohibited. Health Canada does not assume liability for the accuracy or authenticity of the information submitted in case reports.
Due to time constraints relating to the production of this publication, information published may not reflect the most current information.
Report a problem or mistake on this page
- Date modified: